ArticlePharmaceutical biology2021
Erzhi pills ameliorate cognitive dysfunction and alter proteomic hippocampus profiles induced by d-galactose and Aβ
Article in Pharmaceutical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Natural compounds as multitarget agents in Alzheimer's diseases: evidence fromFrontiers in pharmacology · 2026Pooled it
- Protective Role of Erzhi Pills in HBiochemical genetics · 2026Article
- The modern scientific interpretation of ancient wisdom: a review of the phytochemistry and pharmacology of Erzhi Pill and its constituent botanical drugs.Frontiers in pharmacology · 2026Review
- Traditional Chinese Medicine-derived formulations and extracts modulating the PI3K/AKT pathway in Alzheimer's disease.Frontiers in pharmacology · 2025Review
- Article
- A review of botany, phytochemistry, pharmacology, and applications of the herb with the homology of medicine and food:Frontiers in pharmacology · 2024Review
- Erzhiwan Ameliorates Restraint Stress- and Monobenzone-Induced Depigmentation in Mice by Inhibiting Macrophage Migration Inhibitory Factor and 8-Hydroxy-2-Deoxyguanosine.Clinical, cosmetic and investigational dermatology · 2024Article
- Attenuation of estrogen and its receptors in the post-menopausal stage exacerbates dyslipidemia and leads to cognitive impairment.Molecular brain · 2023Article
- Promotion of Hair Regrowth in Androgenetic Alopecia with Supplemented Erzhi Wan: Exploring Its Mechanism Using Network Pharmacology and Molecular Docking.Clinical, cosmetic and investigational dermatology · 2023Article
- Article
- Effect of Yisui Multipurpose Soup's Amelioration on D-Galactose-Induced Neuronal Cells.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Roles of traditional chinese medicine regulating neuroendocrinology on AD treatment.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextErzhi pills are a classic Chinese medicine prescription, but their effects on Alzheimer's disease (AD) are not clear.
objectiveThe protective effects of Erzhi pills in AD rats and their potential mechanisms were investigated. MATERIALS AND
methodsAn AD rat model was established by ovariectomy combined with d-galactose and Aβ
resultsErzhi pills (1.5, 0.75 g/kg) markedly reduced escape latencies on the MWM, increased numbers of platform crossings, numbers of neurons, Nissl bodies, oestrogen levels (100.18, 43.04 pg/mL), and ERβ-positive cells (57.42, 39.83); Aβ DISCUSSION AND
conclusionErzhi pills may serve as a potential agent for AD therapeutics by improving learning and memory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.